CARsgen Therapeutics Holdings Limited (CRTHF PINK) stock market data APIs

$0.7606 0(0%)
as of July 3, 2025
Try our APIs with free plan!

CARsgen Therapeutics Holdings Limited Financial Data Overview

Price chart is built with Anychart

CARsgen Therapeutics Holdings Limited, an investment holding company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies, solid tumors, and autoimmune diseases in China. Its products include CT053 for the treatment of relapsed/refractory multiple myeloma (R/R MM). The company is also developing autologous CAR-T product candidates, including CT041, which targets Claudin 18.2, is in phase II/III clinical trial for gastric/gastroesophageal junction cancer and pancreatic cancer, as well as in phase I clinical trial for gastric or pancreatic cancer; CT011, which is in phase I clinical trial to treat hepatocellular carcinoma (HCC); and CT071, that is in Phase I clinical trial for the treatment of R/R MM, relapsed/refractory primary plasma cell leukemia (R/R pPCL), relapsed/refractory plasma cell leukemia (R/R PCL), and newly diagnosed multiple myeloma. In addition, it is developing CT0590 and CT059X, which target B-cell maturation antigen and are in phase I clinical trial for the treatment of R/R/ MM and R/R PCL; KJ-C2219, which is in phase I for the treatment of B-cell malignancies, systemic lupus erythematosus, and systemic sclerosis; and KJ-C2320 for acute myeloid leukemia (AML) that is in phase I. Further, the company develops KJ-C2114 that are in the pre-clinical stage for the treatment of solid tumors; and KJ-C2526, which is in the pre-clinical stage to treat AML, other malignancies, and senescence. The company was founded in 2014 and is headquartered in Shanghai, China.

Prev. Close 0.7606
Open 0.7606
High 0.7606
Low 0.7606
52 wk Range 0.7465-0.76
Market Cap 418 M
Shares Outstanding 549 M
Revenue 39 425 K
Beta 0.482

Why to choose EODHD?

Prices start at $19.99

24/7 Live support

Robust, powerful and reliable data

API Simplicity of a few lines of code


Try our APIs
with free plan!

Or get access to advanced financial data starting only $19.99

TRY NOW

Get CARsgen Therapeutics Holdings Limited data using free add-ons & libraries


Get CARsgen Therapeutics Holdings Limited Fundamental Data

CARsgen Therapeutics Holdings Limited Fundamental data includes:

  • Net Revenue: 39 425 K
  • EBITDA: -686 611 968
  • Earnings Per Share:
  • Income Statements
  • Balance Sheets
  • Cash flows

Plans with Fundamental data

Starting from

$ 59.99 /mo.
COMPARE PLANS

End-of-day & Earnings data

Get CARsgen Therapeutics Holdings Limited Earnings data

Calendar & News package for

$ 19.99 /mo.

What’s included:

  • Latest Release: NaN
  • EPS/Forecast: NaN
GET THE PACKAGE

Get CARsgen Therapeutics Holdings Limited End-of-day data

EOD Historical Data package for

$ 19.99 /mo.

What’s included:

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends
GET THE PACKAGE

CARsgen Therapeutics Holdings Limited News

Get Apple Inc fresh news feed via Financial News API

Calendar & News package for

$19.99/mo.

Try our APIs
with free plan!

Or get access to advanced financial data starting only $19.99

TRY NOW
  • Flexibility: No long-term commitments, just a minimum of one month
  • Instant access: Get your API key and instructions within seconds of subscribing
  • Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.

What’s included:

  • API Calls per Day: 100 000/day
  • API Requests per Min.: 1000/minute
  • Type of Usage: Personal use

Data access:

Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.

GET THE PACKAGE
Chat